deltatrials
Unknown PHASE4 NCT00188188

Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease

Endothelial Dysfunction in Systemic Lupus Erythematosus: Its Contribution to Abnormalities in Coronary Perfusion.

Sponsor: Heart and Stroke Foundation of Canada

Conditions Systemic Lupus Erythematosus
Interventions quinipril
Updated 5 times since 2017 Last updated: Dec 28, 2005 Started: Mar 31, 2002

A PHASE4 clinical study on Systemic Lupus Erythematosus, this trial is ongoing. The trial is conducted by Heart and Stroke Foundation of Canada and has accumulated 5 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE4

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE4

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE4

  5. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE4

    First recorded

Mar 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Heart and Stroke Foundation of Canada
  • University Health Network, Toronto
Data source: University Health Network, Toronto

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Toronto, Canada